Theravance Biopharma (TBPH) Revenue (2013 - 2026)

Theravance Biopharma (TBPH) has 14 years of Revenue data on file, last reported at $17.7 million in Q1 2026.

• Revenue for Q1 2026 came in at $17.7 million, up 15.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $88.9 million (up 36.19% YoY), and the FY2025 annual result was $7.5 million, down 88.35% from the prior year.
• Revenue fell to $17.7 million in Q1 2026 per TBPH's latest filing, from $25.0 million in the prior quarter.
• Over five years, Revenue peaked at $26.2 million in Q2 2025 and troughed at $2.5 million in Q1 2022.
• A 5-year average of $15.7 million and a median of $15.4 million in 2025 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue plunged 82.46% in 2022, then surged 316.68% in 2023.
• A 5-year view of Revenue shows it stood at $14.6 million in 2022, then grew by 19.91% to $17.6 million in 2023, then increased by 6.77% to $18.8 million in 2024, then soared by 33.3% to $25.0 million in 2025, then declined by 29.2% to $17.7 million in 2026.
• Business Quant data shows TBPH's Revenue at $17.7 million in Q1 2026, $25.0 million in Q4 2025, and $20.0 million in Q3 2025.